Necrobiosis lipoidica (NL) is a rare granulomatous disease of hitherto unclear etiology frequently seen in patients with diabetes. Characterized by its potential for ulcerations, it often presents a serious burden for those affected. There are currently neither German nor European guidelines for the treatment of NL. At the same time, standard treatment with topical or intralesional corticosteroids does not always show satisfactory results. We therefore set out to evaluate whether the various treatment regimens published since 2000 have actually expanded the therapeutic armamentarium in a relevant manner. Included were all publications that described more than one patient being treated with any given therapeutic modality. Overall, we analyzed data for 16 different treatment regimens reported in 49 publications.
Introduction
Necrobiosis lipoidica (NL) is a rare granulomatous disease of hitherto unclear etiology. Histologically, it is characterized by collagen degeneration, granuloma formation, and endothelial swelling. First described by Oppenheim in 1929 [ 1 ] , various studies have shown the prevalence of diabetes -at the time of NL diagnosis -to be somewhere between 30 % and 60 % [ 2 ] . Conversely, only approximately 3 % of diabetics develop NL over the course of their disease. Women are more frequently affected than men.
Clinically, NL is characterized by yellowish-brown, bizarrely shaped, well-demarcated plaques with preferation of the extensor aspects of the lower extremities. Ulceration occurs in roughly 30 % of cases.
Given its unknown etiology and the lack of evidence for a pathogenetic model, there is to date neither an approved treatment nor are there German or European guidelines. At the same time, treatment of NL in daily practice frequently poses a challenge as the response to "tried and tested" (mainly corticosteroid-based) topical therapies is far from satisfactory.
The objective of the present article is to systematically review and assess study data with respect to the treatment of NL currently available.
Studies and methods
The literature research for this study was done on Pubmed ( http://pubmed.gov ) using the search items "necrobiosis lipoidica" and "treatment". In order to limit the number of hits to more recent therapeutic approaches, only those articles were taken into consideration that have been published between January 2000 and August 2016. As there are hardly any randomized controlled trials on the treatment of NL, case series and individual case reports were also included in the evaluation. Only those publications were included that described more than one patient being treated with any given therapeutic regimen over a given period of time (for instance, at least two individual case reports or a publication with at least two patients treated with the same regimen).
As regards the assessment of therapeutic success described in these publications, the problem arises that clinical presentations vary (with or without ulceration), and, at the same time, there is no comprehensive cross-study defi nition of what constitutes successful treatment.
"Complete response" was therefore defi ned as noninfl ammatory residual lesions, possibly with scar formation, at the end of the observation period. Cases marked by only partial subsidence and persistent residual infl ammation were regarded as "partial response". Publications that described a certain treatment approach but failed to provide information on the percentage of patients with partial or complete response (according to the aforementioned defi nition) were excluded from the analysis. Any ulceration and its healing were assessed separately. Mere healing of the ulceration (with persistent infl ammation of the underlying plaque) as well as lack of information with respect to said infl ammation were regarded as "partial response". If there was any information on recurrences following cessation of treatment, this was documented; in case no such information was given, it was noted as missing information.
The publications analyzed are presented in Table 1 . For clearer illustration of our fi ndings, Figure 1 depicts an amalgamation of various publications on the same active agent/ mode of action. In order to allow for a quick overview of the total number of patients treated with a given method as well as the proportion of patients who responded, these parameters are presented in a horizontal and a vertical bar chart (last two columns). The height of the green bar represents the proportion of patients with a "complete response"; the height of the yellow bar depicts the proportion of those who experienced clinical improvement; the red bar signifi es lack of response or exacerbation.
Findings and discussion
As can be seen from Figure 1 , the largest amount of (published) data with regard to the treatment of NL exists for the application of phototherapy (primarily topical PUVA therapy), with almost 100 documented patients. Just over one-half of patients undergoing phototherapy responded to treatment. Topical PUVA therapy achieved a partial or complete response in around two-thirds of cases. With 25 documented cases, there is relatively broad clinical experience with photodynamic therapy (PDT). However, nearly 50 % of patients did not show any improvement on PDT.
The second largest group of publications involved the use of classic systemic antiinfl ammatory and immunomodulating agents. Within this group less than 10 % of patients treated with fumaric acid esters showed no improvement. Similarly, only 10 % of patients treated with chloroquine and hydroxychloroquine did not show improvement. It should be pointed out, though, that only ten cases were published during the period under review. While all patients on cyclosporine A showed a complete response, the number of documented cases (n = 3) is very small.
With regard to biologics, the published reports only described the use of agents that inhibit the effects of tumor necrosis factor α (TNF α ). Given that TNF α is thought to play a signifi cant role in granuloma formation (a key characteristic of necrobiosis lipoidica), this should not be surprising. Of the 13 patients published to date who were treated with TNF α inhibitors, only one patient (8 %) showed no improvement. Around 70 % of patients treated with biologics achieved a complete response.
As regards pentoxifylline, all four patients treated experienced a complete response. Topical application of tacrolimus resulted in a partial or complete response in roughly 80 % of patients.
The publications by Mazour et al. [ 46 ] and Souza et al. [ 47 ] are of interest from a pathophysiological rather than a therapeutic perspective as they reported on the complete resolution of NL lesions following a pancreas transplant. This observation might provide support to the theory that -in diabetes-associated cases of NL -the formation and deposition of glycoproteins possibly constitutes the initial step in endothelial swelling and subsequent granuloma formation [ 51 ] .
Based on the data available, it is impossible to give a clear treatment recommendation or even rank the various therapeutic options. From the last two columns of Figure 1 , one may readily discern that with an increase in the number of patients treated with a given modality, there is a decrease in the proportion of patients who achieved a complete response. The treatment methods with only few documented/ published patients therefore only "appear" to be more successful. We believe that this phenomenon is caused by marked publication bias. Given the rarity of the disease, there is a very large number of individual case reports or case series that were presumably only submitted for publication because of the positive therapeutic effects described therein. Individual case reports of negative experiences with the same active agent are typically not submitted, and likely not accepted, either.
Conclusion
The present review provides a critical assessment of reports on the treatment of NL published since 2000. Stating the Motolese et al. [ 50 ] 2015 Table 1 Continued.
overall number of patients treated with a given therapeutic modality, it also presents the treatment response associated with the various regimens ( Figure 1 ). It can be seen that with an increase in the number of patients treated, the proportion of patients successfully treated actually decreases. Thus, the common practice of starting treatment with topical or intralesional corticosteroid therapy can -in our view -still be recommended. Other therapeutic options such as acetylsalicylic acid plus dipyridamole or skin grafts should also still be considered. While these were not addressed in this review -there were no corresponding publications during the period in question -earlier publications did show their therapeutic effi cacy. Various forms of phototherapy as well as systemic treatments have been shown to be successful, and can therefore be used as second-line therapy. In this context, it is up to physicians to come to a decision (together with their patients), either in favor of higher evidence (greater number of patients treated) or in favor of a higher complete response rate (as documented to date). 
